{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:34:50Z","timestamp":1762432490584,"version":"3.27.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-024-02993-x","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T18:04:00Z","timestamp":1729188240000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of inhaled beclometasone dipropionate\/formoterol fumarate\/glycopyrronium vs. beclometasone dipropionate\/formoterol fumarate and placebo on lung hyperinflation and exercise endurance in chronic obstructive pulmonary disease: a randomised controlled trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Henrik","family":"Watz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Marie","family":"Kirsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ludwig-Sengpiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kr\u00fcll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Mroz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Georges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Varoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9mi","family":"Charretier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Vele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Galkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"2993_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [Internet]. 2024 [cited 2024 Sep 4]. https:\/\/goldcopd.org\/2024-gold-report\/"},{"key":"2993_CR2","doi-asserted-by":"publisher","first-page":"106807","DOI":"10.1016\/j.rmed.2022.106807","volume":"197","author":"D Mannino","year":"2022","unstructured":"Mannino D, Bogart M, Wu B, Germain G, Lalibert\u00e9 F, MacKnight SD, et al. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: a real-world study. Respir Med. 2022;197:106807. https:\/\/doi.org\/10.1016\/j.rmed.2022.106807.","journal-title":"Respir Med"},{"key":"2993_CR3","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","volume":"388","author":"D Singh","year":"2016","unstructured":"Singh D, Papi A, Corradi M, Pavli\u0161ov\u00e1 I, Montagna I, Francisco C, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388:963\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(16)31354-X.","journal-title":"Lancet"},{"key":"2993_CR4","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","volume":"389","author":"J Vestbo","year":"2017","unstructured":"Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389:1919\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(17)30188-5.","journal-title":"Lancet"},{"key":"2993_CR5","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","volume":"391","author":"A Papi","year":"2018","unstructured":"Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391:1076\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(18)30206-X.","journal-title":"Lancet"},{"key":"2993_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.amjmed.2006.08.005","volume":"119","author":"JZ Reardon","year":"2006","unstructured":"Reardon JZ, Lareau SC, ZuWallack R. Functional status and quality of life in chronic obstructive pulmonary disease. Am J Med. 2006;119:32\u20137. https:\/\/doi.org\/10.1016\/j.amjmed.2006.08.005.","journal-title":"Am J Med"},{"key":"2993_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/15412550701480620","volume":"4","author":"R ZuWallack","year":"2007","unstructured":"ZuWallack R. How are you doing? What are you doing? Differing perspectives in the assessment of individuals with COPD. COPD. 2007;4:293\u20137. https:\/\/doi.org\/10.1080\/15412550701480620.","journal-title":"COPD"},{"key":"2993_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2147\/COPD.S32451","volume":"7","author":"KM Beeh","year":"2012","unstructured":"Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503\u201313. https:\/\/doi.org\/10.2147\/COPD.S32451.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2993_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/1471-2466-14-209","volume":"14","author":"KM Beeh","year":"2014","unstructured":"Beeh KM, Watz H, Puente-Maestu L, de Teresa L, Jarreta D, Caracta C, et al. Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial. BMC Pulm Med. 2014;14:209. https:\/\/doi.org\/10.1186\/1471-2466-14-209.","journal-title":"BMC Pulm Med"},{"key":"2993_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.rmed.2014.01.006","volume":"108","author":"K-M Beeh","year":"2014","unstructured":"Beeh K-M, Korn S, Beier J, Jadayel D, Henley M, D\u2019Andrea P, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014;108:584\u201392. https:\/\/doi.org\/10.1016\/j.rmed.2014.01.006.","journal-title":"Respir Med"},{"key":"2993_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3109\/15412555.2011.594464","volume":"8","author":"K-M Beeh","year":"2011","unstructured":"Beeh K-M, Wagner F, Khindri S, Drollmann AF. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD. 2011;8:340\u20135. https:\/\/doi.org\/10.3109\/15412555.2011.594464.","journal-title":"COPD"},{"key":"2993_CR12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/J.RMED.2013.01.009","volume":"107","author":"JA Guenette","year":"2013","unstructured":"Guenette JA, Webb KA, O\u2019Donnell DE. Effect of fluticasone\/salmeterol combination on dyspnea and respiratory mechanics in mild-to-moderate COPD. Respir Med. 2013;107:708\u201316. https:\/\/doi.org\/10.1016\/J.RMED.2013.01.009.","journal-title":"Respir Med"},{"key":"2993_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/S12931-016-0389-5","volume":"17","author":"F Maltais","year":"2016","unstructured":"Maltais F, Kirsten AM, Hamilton A, De Sousa D, Vo\u00df F, Decramer M. Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies. Respir Res. 2016;17:77. https:\/\/doi.org\/10.1186\/S12931-016-0389-5.","journal-title":"Respir Res"},{"key":"2993_CR14","doi-asserted-by":"publisher","first-page":"175346581875509","DOI":"10.1177\/1753465818755091","volume":"12","author":"F Maltais","year":"2018","unstructured":"Maltais F, O\u2019Donnell D, G\u00e1ldiz Iturri JB, Kirsten AM, Singh D, Hamilton A, et al. Effect of 12 weeks of once-daily tiotropium\/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2018;12:1753465818755091. https:\/\/doi.org\/10.1177\/1753465818755091.","journal-title":"Ther Adv Respir Dis"},{"key":"2993_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/1753465814559209","volume":"8","author":"F Maltais","year":"2014","unstructured":"Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, et al. Effects of a combination of umeclidinium\/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis. 2014;8:169\u201381. https:\/\/doi.org\/10.1177\/1753465814559209.","journal-title":"Ther Adv Respir Dis"},{"key":"2993_CR16","doi-asserted-by":"publisher","first-page":"1601348","DOI":"10.1183\/13993003.01348-2016","volume":"49","author":"DE O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell DE, Casaburi R, Frith P, Kirsten A, De Sousa D, Hamilton A, et al. Effects of combined tiotropium\/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J. 2017;49:1601348. https:\/\/doi.org\/10.1183\/13993003.01348-2016.","journal-title":"Eur Respir J"},{"key":"2993_CR17","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1183\/09031936.04.00116004","volume":"23","author":"DEE O\u2019Donnell","year":"2004","unstructured":"O\u2019Donnell DEE, Fl\u00fcge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832\u201340. https:\/\/doi.org\/10.1183\/09031936.04.00116004.","journal-title":"Eur Respir J"},{"key":"2993_CR18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1378\/chest.130.3.647","volume":"130","author":"DE O\u2019Donnell","year":"2006","unstructured":"O\u2019Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, et al. Effect of fluticasone propionate\/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest. 2006;130:647\u201356. https:\/\/doi.org\/10.1378\/chest.130.3.647.","journal-title":"Chest"},{"key":"2993_CR19","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.rmed.2011.03.014","volume":"105","author":"DE O\u2019Donnell","year":"2011","unstructured":"O\u2019Donnell DE, Casaburi R, Vincken W, Puente-Maestu L, Swales J, Lawrence D, et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med. 2011;105:1030\u20136. https:\/\/doi.org\/10.1016\/j.rmed.2011.03.014.","journal-title":"Respir Med"},{"key":"2993_CR20","doi-asserted-by":"publisher","first-page":"00073","DOI":"10.1183\/23120541.00073-2017","volume":"4","author":"JH Riley","year":"2018","unstructured":"Riley JH, Kalberg CJ, Donald A, Lipson DA, Shoaib M, Tombs L. Effects of umeclidinium\/vilanterol on exercise endurance in COPD: a randomised study. ERJ Open Res. 2018;4:00073\u20132017. https:\/\/doi.org\/10.1183\/23120541.00073-2017.","journal-title":"ERJ Open Res"},{"key":"2993_CR21","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1164\/RCCM.201706-1288OC","volume":"198","author":"T Troosters","year":"2018","unstructured":"Troosters T, Maltais F, Leidy N, Lavoie KL, Sedeno M, Janssens W, et al. Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198:1021\u201332. https:\/\/doi.org\/10.1164\/RCCM.201706-1288OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"2993_CR22","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.2147\/COPD.S143488","volume":"12","author":"H Watz","year":"2017","unstructured":"Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, et al. ACTIVATE: the effect of aclidinium\/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2545\u201358. https:\/\/doi.org\/10.2147\/COPD.S143488.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2993_CR23","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.rmed.2010.07.006","volume":"104","author":"H Worth","year":"2010","unstructured":"Worth H, F\u00f6rster K, Eriksson G, Nihl\u00e9n U, Peterson S, Magnussen H. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. Respir Med. 2010;104:1450\u20139. https:\/\/doi.org\/10.1016\/j.rmed.2010.07.006.","journal-title":"Respir Med"},{"key":"2993_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1183\/13993003.00745-2015","volume":"47","author":"L Puente-Maestu","year":"2016","unstructured":"Puente-Maestu L, Palange P, Casaburi R, Laveneziana P, Maltais F, Neder JA, et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J. 2016;47:429\u201360. https:\/\/doi.org\/10.1183\/13993003.00745-2015.","journal-title":"Eur Respir J"},{"key":"2993_CR25","volume-title":"Principles of Exercise Testing and Interpretation: including pathophysiology and clinical applications","author":"K Wasserman","year":"2011","unstructured":"Wasserman K, Hansen J, Sietsema K, Sue D, Stringer W, Sun X-G, et al. Principles of Exercise Testing and Interpretation: including pathophysiology and clinical applications. 5th ed. [Philadelphia, PA: USA]; 2011.","edition":"5"},{"key":"2993_CR26","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1164\/ARRD.1982.126.5.825","volume":"126","author":"JGW Burdon","year":"1982","unstructured":"Burdon JGW, Juniper EF, Killian KJ, Hargreave FE, Campbell EJ. The perception of breathlessness in asthma. Am Rev Respir Dis. 1982;126:825\u20138. https:\/\/doi.org\/10.1164\/ARRD.1982.126.5.825.","journal-title":"Am Rev Respir Dis"},{"key":"2993_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/S12931-018-0721-3","volume":"19","author":"F Di Marco","year":"2018","unstructured":"Di Marco F, Sotgiu G, Santus P, O\u2019Donnell DE, Beeh KM, Dore S, et al. Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis. Respir Res. 2018;19:18. https:\/\/doi.org\/10.1186\/S12931-018-0721-3.","journal-title":"Respir Res"},{"key":"2993_CR28","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1183\/09031936.95.08030492","volume":"8","author":"J Stocks","year":"1995","unstructured":"Stocks J, Quanjer PHH. Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung volume measurements. Official Statement of the European respiratory society. Eur Respir J. 1995;8:492\u2013506. https:\/\/doi.org\/10.1183\/09031936.95.08030492.","journal-title":"Eur Respir J"},{"key":"2993_CR29","doi-asserted-by":"publisher","unstructured":"Casaburi R, Merrill D, Leidy NK, Locantore N, Dolmage T, Garcia-Aymerich J, et al. Validation of constant work rate cycling endurance time for use in chronic obstructive pulmonary disease clinical trials. Ann Am Thorac Soc. 2023;Online early. https:\/\/doi.org\/10.1513\/AnnalsATS.202305-480OC.","DOI":"10.1513\/AnnalsATS.202305-480OC"},{"key":"2993_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12931-020-01589-5","volume":"21","author":"J Dean","year":"2020","unstructured":"Dean J, Panainte C, Khan N, Singh D. The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone\/formoterol\/glycopyrronium on gas trapping in COPD. Respir Res. 2020;21:323. https:\/\/doi.org\/10.1186\/s12931-020-01589-5.","journal-title":"Respir Res"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02993-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-024-02993-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02993-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T18:08:38Z","timestamp":1729188518000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-024-02993-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2993"],"URL":"https:\/\/doi.org\/10.1186\/s12931-024-02993-x","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]},"assertion":[{"value":"19 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involves human participants and was approved by the independent ethics committees or research boards at each institution. Participants gave written informed consent to participate in the study before taking part.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"In addition to writing support, the authors have the following conflicts of interest to declare.\u00a0HW declares that his employer, Pulmonary Research Institute at Lung Clinic Grosshansdorf, was contracted for the clinical work in this study. Outside the scope of the current manuscript he declares consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel, and participation on a data safety monitoring board or advisory board, all for AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, and Sanofi. In addition, he is a speaker in COPD for the German Center for Lung Research.\u00a0AMK declares that her employer, Pulmonary Research Institute at Lung Clinic Grosshansdorf, was contracted for the clinical work in this study. She has no other conflicts of interest to disclose.\u00a0ALS declares that her employer, KLB Gesundheitsforschung L\u00fcbeck GmbH, was contracted for the clinical work in this study. She has no other conflicts of interest to disclose.\u00a0MK declares payments for lecture and presentations from AstraZeneca, Chiesi, and Berlin Chemie, all outside the scope of the current manuscript.\u00a0RMM declares that his employer, Centrum Medycyny Oddechowej Mroz Spolka jawna, was contracted for the clinical work in this study. Outside the scope of the current manuscript he declares consulting fees, payment or honoraria for lectures, presentations, manuscript writing or educational events, support for attending meetings and\/or travel, and participation in advisory boards from Aretheia Therepeutics, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MSD, Novartis, Sanofi and Takeda.\u00a0GG, GV, RC, MC, AV, and DG are employees of Chiesi, the sponsor of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"378"}}